Combined down-regulation by aromatase inhibitor and GnRH-agonist in IVF patients with endometriomas-A pilot study

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Combined down-regulation by aromatase inhibitor and GnRH-agonist in IVF patients with endometriomas-A pilot study. / Lossl, Kristine; Loft, Anne; Freiesleben, Nina L C; Bangsbøll, Susanne; Andersen, Claus Yding; Pedersen, Anette T; Hartwell, Dorthe; Andersen, Anders Nyboe; Løssl, Kristine; Loft, Anne; Freiesleben, Nina L C; Bangsbøll, Susanne; Andersen, Claus Yding; Pedersen, Anette T; Hartwell, Dorthe; Andersen, Anders Nyboe.

In: European Journal of Obstetrics & Gynecology and Reproductive Biology, Vol. 144, No. 1, 01.05.2009, p. 48-53.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Lossl, K, Loft, A, Freiesleben, NLC, Bangsbøll, S, Andersen, CY, Pedersen, AT, Hartwell, D, Andersen, AN, Løssl, K, Loft, A, Freiesleben, NLC, Bangsbøll, S, Andersen, CY, Pedersen, AT, Hartwell, D & Andersen, AN 2009, 'Combined down-regulation by aromatase inhibitor and GnRH-agonist in IVF patients with endometriomas-A pilot study', European Journal of Obstetrics & Gynecology and Reproductive Biology, vol. 144, no. 1, pp. 48-53. https://doi.org/10.1016/j.ejogrb.2009.02.001, https://doi.org/10.1016/j.ejogrb.2009.02.001

APA

Lossl, K., Loft, A., Freiesleben, N. L. C., Bangsbøll, S., Andersen, C. Y., Pedersen, A. T., Hartwell, D., Andersen, A. N., Løssl, K., Loft, A., Freiesleben, N. L. C., Bangsbøll, S., Andersen, C. Y., Pedersen, A. T., Hartwell, D., & Andersen, A. N. (2009). Combined down-regulation by aromatase inhibitor and GnRH-agonist in IVF patients with endometriomas-A pilot study. European Journal of Obstetrics & Gynecology and Reproductive Biology, 144(1), 48-53. https://doi.org/10.1016/j.ejogrb.2009.02.001, https://doi.org/10.1016/j.ejogrb.2009.02.001

Vancouver

Lossl K, Loft A, Freiesleben NLC, Bangsbøll S, Andersen CY, Pedersen AT et al. Combined down-regulation by aromatase inhibitor and GnRH-agonist in IVF patients with endometriomas-A pilot study. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2009 May 1;144(1):48-53. https://doi.org/10.1016/j.ejogrb.2009.02.001, https://doi.org/10.1016/j.ejogrb.2009.02.001

Author

Lossl, Kristine ; Loft, Anne ; Freiesleben, Nina L C ; Bangsbøll, Susanne ; Andersen, Claus Yding ; Pedersen, Anette T ; Hartwell, Dorthe ; Andersen, Anders Nyboe ; Løssl, Kristine ; Loft, Anne ; Freiesleben, Nina L C ; Bangsbøll, Susanne ; Andersen, Claus Yding ; Pedersen, Anette T ; Hartwell, Dorthe ; Andersen, Anders Nyboe. / Combined down-regulation by aromatase inhibitor and GnRH-agonist in IVF patients with endometriomas-A pilot study. In: European Journal of Obstetrics & Gynecology and Reproductive Biology. 2009 ; Vol. 144, No. 1. pp. 48-53.

Bibtex

@article{6dd8e4a067fa11df928f000ea68e967b,
title = "Combined down-regulation by aromatase inhibitor and GnRH-agonist in IVF patients with endometriomas-A pilot study",
abstract = "OBJECTIVE: The key enzyme in the biosynthesis of estradiol, aromatase, has been demonstrated within endometriosis. Combined administration of aromatase inhibitor and GnRH-agonist may efficiently suppress estrogen biosynthesis through a combined pituitary, ovarian, peripheral and {"}in situ{"} action. The aim of this study was to test the concept of combined down-regulation prior to IVF in patients with endometriomas. STUDY DESIGN: Prospective pilot study in a university-based tertiary fertility clinic including 20 infertile patients with endometriomas undergoing IVF/ICSI. The patients received goserelin 3.6mg sc on treatment Days 1, 28 and 56, and one daily tablet of anastrozole 1mg from Day 1 to Day 69. Controlled ovarian stimulation was initiated from Day 70. Outcome measures were change in endometriomal volume and serum CA125 during down-regulation, standard IVF parameters including pregnancy and delivery rate, and endocrine response. The paired T test and Wilcoxon Signed Rank test were used to analyse paired differences. RESULTS: During the combined down-regulation, the endometriomal volume and the serum CA125 level decreased by 29% (3-39%) and 61% (21-74%), respectively (median (95%CI), P=0.007 and P=0.001). In the IVF/ICSI cycle, the number of oocytes retrieved was 7.5 (6.0-10.0) and the fertilization rate was 0.78 (0.38-1.0). Nine patients (45%) conceived, five (25%) had a clinical pregnancy, and three (15%) delivered healthy children (two singletons and one twin). CONCLUSIONS: Prolonged combined anastrozole and goserelin down-regulation significantly reduces endometriomal volume and serum CA125, and is compatible with IVF pregnancy and delivery. However, a high pregnancy loss was noted.",
author = "Kristine Lossl and Anne Loft and Freiesleben, {Nina L C} and Susanne Bangsb{\o}ll and Andersen, {Claus Yding} and Pedersen, {Anette T} and Dorthe Hartwell and Andersen, {Anders Nyboe} and Kristine L{\o}ssl and Anne Loft and Freiesleben, {Nina L C} and Susanne Bangsb{\o}ll and Andersen, {Claus Yding} and Pedersen, {Anette T} and Dorthe Hartwell and Andersen, {Anders Nyboe}",
note = "Keywords: Adult; Aromatase Inhibitors; CA-125 Antigen; Down-Regulation; Drug Therapy, Combination; Endometriosis; Estrogens; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone; Goserelin; Humans; Nitriles; Pilot Projects; Pregnancy; Pregnancy Outcome; Prospective Studies; Triazoles; Uterine Diseases",
year = "2009",
month = may,
day = "1",
doi = "10.1016/j.ejogrb.2009.02.001",
language = "English",
volume = "144",
pages = "48--53",
journal = "European Journal of Obstetrics, Gynecology and Reproductive Biology",
issn = "0301-2115",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

RIS

TY - JOUR

T1 - Combined down-regulation by aromatase inhibitor and GnRH-agonist in IVF patients with endometriomas-A pilot study

AU - Lossl, Kristine

AU - Loft, Anne

AU - Freiesleben, Nina L C

AU - Bangsbøll, Susanne

AU - Andersen, Claus Yding

AU - Pedersen, Anette T

AU - Hartwell, Dorthe

AU - Andersen, Anders Nyboe

AU - Løssl, Kristine

AU - Loft, Anne

AU - Freiesleben, Nina L C

AU - Bangsbøll, Susanne

AU - Andersen, Claus Yding

AU - Pedersen, Anette T

AU - Hartwell, Dorthe

AU - Andersen, Anders Nyboe

N1 - Keywords: Adult; Aromatase Inhibitors; CA-125 Antigen; Down-Regulation; Drug Therapy, Combination; Endometriosis; Estrogens; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone; Goserelin; Humans; Nitriles; Pilot Projects; Pregnancy; Pregnancy Outcome; Prospective Studies; Triazoles; Uterine Diseases

PY - 2009/5/1

Y1 - 2009/5/1

N2 - OBJECTIVE: The key enzyme in the biosynthesis of estradiol, aromatase, has been demonstrated within endometriosis. Combined administration of aromatase inhibitor and GnRH-agonist may efficiently suppress estrogen biosynthesis through a combined pituitary, ovarian, peripheral and "in situ" action. The aim of this study was to test the concept of combined down-regulation prior to IVF in patients with endometriomas. STUDY DESIGN: Prospective pilot study in a university-based tertiary fertility clinic including 20 infertile patients with endometriomas undergoing IVF/ICSI. The patients received goserelin 3.6mg sc on treatment Days 1, 28 and 56, and one daily tablet of anastrozole 1mg from Day 1 to Day 69. Controlled ovarian stimulation was initiated from Day 70. Outcome measures were change in endometriomal volume and serum CA125 during down-regulation, standard IVF parameters including pregnancy and delivery rate, and endocrine response. The paired T test and Wilcoxon Signed Rank test were used to analyse paired differences. RESULTS: During the combined down-regulation, the endometriomal volume and the serum CA125 level decreased by 29% (3-39%) and 61% (21-74%), respectively (median (95%CI), P=0.007 and P=0.001). In the IVF/ICSI cycle, the number of oocytes retrieved was 7.5 (6.0-10.0) and the fertilization rate was 0.78 (0.38-1.0). Nine patients (45%) conceived, five (25%) had a clinical pregnancy, and three (15%) delivered healthy children (two singletons and one twin). CONCLUSIONS: Prolonged combined anastrozole and goserelin down-regulation significantly reduces endometriomal volume and serum CA125, and is compatible with IVF pregnancy and delivery. However, a high pregnancy loss was noted.

AB - OBJECTIVE: The key enzyme in the biosynthesis of estradiol, aromatase, has been demonstrated within endometriosis. Combined administration of aromatase inhibitor and GnRH-agonist may efficiently suppress estrogen biosynthesis through a combined pituitary, ovarian, peripheral and "in situ" action. The aim of this study was to test the concept of combined down-regulation prior to IVF in patients with endometriomas. STUDY DESIGN: Prospective pilot study in a university-based tertiary fertility clinic including 20 infertile patients with endometriomas undergoing IVF/ICSI. The patients received goserelin 3.6mg sc on treatment Days 1, 28 and 56, and one daily tablet of anastrozole 1mg from Day 1 to Day 69. Controlled ovarian stimulation was initiated from Day 70. Outcome measures were change in endometriomal volume and serum CA125 during down-regulation, standard IVF parameters including pregnancy and delivery rate, and endocrine response. The paired T test and Wilcoxon Signed Rank test were used to analyse paired differences. RESULTS: During the combined down-regulation, the endometriomal volume and the serum CA125 level decreased by 29% (3-39%) and 61% (21-74%), respectively (median (95%CI), P=0.007 and P=0.001). In the IVF/ICSI cycle, the number of oocytes retrieved was 7.5 (6.0-10.0) and the fertilization rate was 0.78 (0.38-1.0). Nine patients (45%) conceived, five (25%) had a clinical pregnancy, and three (15%) delivered healthy children (two singletons and one twin). CONCLUSIONS: Prolonged combined anastrozole and goserelin down-regulation significantly reduces endometriomal volume and serum CA125, and is compatible with IVF pregnancy and delivery. However, a high pregnancy loss was noted.

U2 - 10.1016/j.ejogrb.2009.02.001

DO - 10.1016/j.ejogrb.2009.02.001

M3 - Journal article

C2 - 19261371

VL - 144

SP - 48

EP - 53

JO - European Journal of Obstetrics, Gynecology and Reproductive Biology

JF - European Journal of Obstetrics, Gynecology and Reproductive Biology

SN - 0301-2115

IS - 1

ER -

ID: 19954572